Literature DB >> 21134754

Phosphoramidate pronucleotides of cytostatic 6-aryl-7-deazapurine ribonucleosides.

Pavla Perlíková1, Radek Pohl, Ivan Votruba, Robert Shih, Gabriel Birkuš, Tomáš Cihlář, Michal Hocek.   

Abstract

A series of O-phenyl methyl-, ethyl- and benzylalanyl phosphoramidate pronucleotides derived from cytostatic 6-aryl-7-deazapurine ribonucleosides were prepared by the cross-coupling reactions of the 2',3'-isopropylidene protected 6-chloro-7-deazapurine ribonucleoside phosphoramidates with (het)arylboronic acids or -stannanes followed by deprotection. Most of the prepared prodrugs exerted in vitro cytostatic effects against both solid tumor and lymphoid cancer cells within low micromolar range of concentrations. These activities were in general weaker or comparable to the activities of the parent nucleosides. Additional testing of selected prodrugs suggests that the lack of activity improvement over parent nucleosides is not due to the lack of permeability or inefficient catabolism of alanyl-ester by intracellular hydrolases. More likely, active efflux of prodrugs may play a role in their weak cytotoxic activity.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134754     DOI: 10.1016/j.bmc.2010.11.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

Review 1.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

2.  Efficient synthesis of exo-N-carbamoyl nucleosides: application to the synthesis of phosphoramidate prodrugs.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Org Lett       Date:  2012-05-03       Impact factor: 6.005

Review 3.  Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.

Authors:  Pavla Perlíková; Michal Hocek
Journal:  Med Res Rev       Date:  2017-08-23       Impact factor: 12.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.